Characteristics of poor quality medicines in Peru from 2005-2014

• Autores: Moreno-Exebio, Luis, Sayritupac, Freddy, Rodríguez-Calzado, Javier, Rodríguez-Tanta, Yesenia
• Formato: artículo
• Fecha de Publicación: 2019
• Institución: Universidad Nacional Mayor de San Marcos
• Repositorio: Revistas - Universidad Nacional Mayor de San Marcos
• Lenguaje: español
• OAI Identifier: oai:ojs.csi.unmsm:article/15739
• Enlace del recurso: https://revistasinvestigacion.unmsm.edu.pe/index.php/farma/article/view/15739
• Nivel de acceso: acceso abierto
• Materia: Counterfeit drugs; quality control; Peru; Medicamentos falsificados; control de calidad; Perú

Objectives: Determine the percentage of medicines of poor-quality: Counterfeit and substandard, analyzed at “Quality Control Center (CNCC)” of National Institutes of Health (NIH), Peru in the period 2005-2014 and determine their types and features. Materials and Methods: A form was created to pick up relevant data directly from CNCC reports and from the Integrated System of Lab Management (SIGEL). Results: The percentage of counterfeit drugs relative to to total drugs evaluated was: 3,0 % in 2005, 5,0 % in 2006, 7,3 % in 2007, and 9,2 % in 2008, 11,4 % in 2009, 6,7 % in 2010, 9,9 % in 2011, 10,6 % in 2012, 8,4 % in 2013 and 7,6 % in 2014. The main groups of counterfeit drugs, classified according to Anatomical Therapeutic Chemical Classification System according to WHO were: Nervous system (21,9 %); antinfectives per sistemic use (20,8 %) and musculo-skeletal system (18,4 %). The most common type of forgery occurred in cases where the drug contained the correct amount of active ingredients, but the manufacturer was not the same that the one stated (44,3 %) and drugs that did not contain active ingredient (37,4 %). The average percentage of substandard quality was 6,8 % between 2005-2014. In the last three years critical tests of this medicines corresponds to 73 %. Conclusions: During the period 2005 and 2009 there was an increased percentage of counterfeit medicines, between 2010 and 2014 this percentage diminished. Respect to substandard medicines, the major percentage corresponds to critical tests that affect severely quality of medicines.